MAP2K7 and ovarian carcinoma: For the top three enriched pathways of AZD6244 treatment, there was a strong cross-talk effect between MEK and estrogen receptor signaling pathway [39] and the AZD6244 treatment was verified to reverse antiestrogen resistance in ovarian cancer [40,41].